German science and technology company Merck KGaA (ETR:MRK) said on Thursday that it has commenced a Phase III clinical trial to evaluate the efficacy and safety of oral cladribine for the treatment of generalised Myasthenia Gravis (gMG).
gMG is a rare autoimmune disorder that causes muscle weakness, significantly impacting patients' lives.
Cladribine, a potential first-line oral therapy for gMG, is designed to target B and T lymphocytes, believed to be the root cause of the disease. By selectively reducing these cells, cladribine aims to slow the progression of gMG and improve patients' quality of life.
"This treatment approach holds the promise of achieving a high degree of disease activity control, offering greatly improved convenience, and ultimately enabling patients to live their lives as normally as possible," said Jan Klatt, head of Development Unit Neurology & Immunology for the Healthcare business of Merck KGaA.
Veralox Therapeutics agrees Nudge Therapeutics acquisition
Johnson & Johnson granted Priority Review for nipocalimab in gMG
Hemogenyx Pharmaceuticals raises GBP340,000 for AML clinical trials
Hemogenyx Pharmaceuticals announces first clinical site for HG-CT-1 Phase I trial
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment
Breckenridge Pharmaceutical launches FDA approved methadone injection
Hansa Biopharma reports positive Phase 2 imlifidase results
Nona Biosciences signs research collaboration and licence agreement with Candid Therapeutics
Gilead Sciences secures positive CHMP opinion for seladelpar in PBC treatment
Full Circles Therapeutics advances non-viral gene editing innovation
Hansa Biopharma completes enrolment in anti-GBM disease trial
Transposon Therapeutics acquires portfolio of novel nucleoside analogues from PrimeFour Therapeutics
Adicet Bio doses first patient in Phase 1 trial of ADI-001 for lupus nephritis
Pulmatrix announces merger with Cullgen to advance targeted protein degradation
Faron Pharmaceuticals files patent for soluble Clever-1 in autoimmune disease treatment